Talking HealthTech

The episode delivers solid technical and practical insights about radar-based vital sign monitoring and its clinical applications, particularly around the POVC scoring system and baseline deviation detection. However, substantial portions are devoted to promotional content (THT membership plugs), general healthcare workflow discussions, and repetitive explanations of the technology's advantages over alternatives, which dilutes insight density.

“We are collecting 6 to 10,000 measurements of your breathing and your heart rate every night, just you go to bed, you wake up and you already collected that many times.”

“We are in the business of informing, not alerting. Alerting is reactive care. Informing is proactive care. Alerting is after something happens. Informing is before something happens.”

The framing of radar-based monitoring as a proactive, predictive tool rather than reactive alerting is somewhat novel, and the specific POVC (Probability of Baseline Change Score) concept offers a fresh perspective on personalized baseline monitoring. However, the broader narrative - technology-enabled early detection, workflow optimization, cost reduction - follows well-worn healthcare innovation templates. The fundamental value proposition is not particularly contrarian.

“We are informing the staff which of the residents or which of the hundred that you need to prioritize, you need to focus on care.”

“the thing that people don't really associate radars is with the accuracy of the measurements as well as the unique information that you can collect with radar.”

Sam Yang as CEO/co-founder of a clinically-validated medtech company with FDA Class II clearance, 49,000 deployed patient instances, and partnerships across multiple health systems demonstrates legitimate operational credibility. Andy Hurt as head of strategic accounts at Aerocom with direct access to facility managers and clinicians also brings practitioner-level engagement. Both have skin in the game, though neither is a senior executive at a major health system or venture-backed scale.

“I'm the CEO and co founder for a medtech startup company called Xander Cardian and we specialize in using radars to collect your heart rate and breathing rate”

“I focus in the Australian, New Zealand market, primarily focused in the health sector. My job is to spend all my days talking to clinicians, facility managers, IT people”

The episode provides concrete data points: 49,000 deployed patients monitored, 75.6% of hospital transfers preceded by 7-day early alarm, 3-5 residents flagged per 100 beds on average, 6-10,000 measurements per night, FDA Class II clearance, and TGA clearance across six countries. The UTI scenario and Ebola use case add specificity. However, claims about POVC accuracy, baseline deviation detection rates, and cost savings are stated but not independently validated or broken down with granular ROI metrics.

“we have deployed over 49,000, uh, so we have monitored, sorry, 49,000 unique patients and uh, they're all tied to an EMR system in the US called Point Clear Care.”

“out of 100 beds on average. So out of 100 beds in a skilled nursing facility we are able to pick out that three to five uh, residents have a deviation from their baseline.”

Host Peter Birch asks reasonable setup questions and follows the conversational thread logically, but rarely challenges claims, dig deeper into limitations, or push back on vendor narratives. Questions are often softball ('tell us more about the technology'), and there is minimal skeptical probing around implementation barriers, false positives, alarm fatigue trade-offs, or cost-benefit trade-offs at scale. The conversation feels like a feature-length product walkthrough rather than substantive scrutiny.

“Maybe tell us a bit more about the technology there, Sam?”

“So the use case definition and working with the different um, parts of the business really gives us the ability to be able to work with them”